Lexicon Pharmaceuticals, Inc.
LXRX
$0.53
-$0.0019-0.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 32.14% | -28.28% | -18.98% | -51.55% | -63.17% |
| Total Depreciation and Amortization | -14.97% | -16.56% | -3.47% | 28.57% | 42.72% |
| Total Amortization of Deferred Charges | -35.11% | -34.95% | 92.31% | 95.09% | 79.13% |
| Total Other Non-Cash Items | -100.70% | 241.75% | -100.66% | 19.36% | -16.85% |
| Change in Net Operating Assets | 375.15% | 23.41% | 66.34% | -230.45% | -182.16% |
| Cash from Operations | 57.48% | -28.83% | -27.34% | -74.39% | -134.35% |
| Capital Expenditure | -- | -269.88% | -79.86% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.39% | 237.03% | 83.79% | -993.15% | 104.16% |
| Cash from Investing | 3.47% | 235.96% | 83.48% | -1,011.47% | 114.69% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -109.95% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -10,300.00% | -336.19% | -100.01% | 29,151.33% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,279.91% | 98.69% | -179.82% | 463.89% | -95.10% |